
ZANAMIVIR
| ZANAMIVIR (zan'a-mi-vir) Relenza Classifications: antiviral; Therapeutic: antiinfluenza Pregnancy Category: C |
Availability
5 mg/Rotadisk blister
Action
Inhibitor of influenza A and B viral enzyme; does not permit the release of newly formed viruses from the surface of the infected cells.
Therapeutic Effect
Prevents viral spread across the mucus lining of the respiratory tract, and inhibits the replication of influenza A and B virus. Relieves flu-like symptoms.
Uses
Uncomplicated acute influenza in patients symptomatic <2 d.
Contraindications
Hypersensitivity to zanamivir or milk protein; severe renal impairment, renal failure; pregnancy (category C); COPD; severe asthma.
Cautious Use
Concurrent use of inhaled medication with inhaled zanamivir; renal impairment; cardiac disease; older adults; severe metablic disease; lactation. Safety and efficacy in children <7 y are unknown. Safe use in prophylactic treatment for children <5 y unknown.
Route & Dosage
| Acute Influenza Adult/Child (>7 y): Inhaled 2 inhalations (one 5 mg blister/inhalation) b.i.d. (approximately 12 h apart) x 5 d Influenza Prophylaxis Adult/Child (>5 y): Inhaled 2 inhalations daily for 10 d (household prophylaxis) or 2 inhalations daily for 28 d (community outbreak) |
Administration
Inhalation- Initiate within 48 h of onset of flu-like symptoms.
- Give any scheduled inhaled bronchodilator before zanamivir.
- Store at 25° C (77° F).
Adverse Effects (≥1%)
Body as a Whole: Headache. CNS: Dizziness. GI: Nausea, diarrhea, vomiting. Respiratory: Nasal symptoms, bronchitis, cough, sinusitis; ear, nose, throat infection.Interactions
Drug: No clinically significant interactions established.Pharmacokinetics
Absorption: 417% of inhaled dose is systemically absorbed. Peak: 12 h. Distribution: <10% protein bound. Metabolism: Not metabolized. Elimination: In urine. Half-Life: 2.55.1 h.Nursing Implications
Patient & Family Education
- Start within 48 h of onset of flu-like symptoms for most effective response.
- Use any scheduled inhaled bronchodilator first; then use zanamivir.
Canadian drug name;
Prototype drug